TLX
Telix·NASDAQ
--
--(--)
--
--(--)
TLX fundamentals
Telix (TLX) released its earnings on Aug 21, 2025: revenue was -- (YoY --), beat estimates; EPS was -- (YoY --), missed estimates.
Revenue / YoY
--
--
EPS / YoY
--
--
Report date
Aug 21, 2025
TLX Earnings Call Summary for Q2,2025
- Revenue Growth: 63% YoY to $390M, driven by Illuccix (30% YoY) and RLS integration.
- Strategic Investments: $82M in R&D (47% YoY) for therapeutics pipeline; $207M cash on hand for M&A.
- RLS Synergies: 50% Illuccix dose volume growth through RLS; U.S. radio metal network expansion planned.
- Clinical Innovation: BiPASS study to reduce prostate cancer biopsies; Gozellix F-18/AlF technology addresses physician preference.
- Therapeutics Catalysts: 3 Phase III trials (prostate, kidney, neuro-oncology) with PDUFA dates in 2025-26.
EPS
Actual | |
Forecast | 0.137676 |
Surprise | 0.00% |
Revenue
Actual | -- |
Forecast | 316.00M |
Surprise | 0.00% |
Earnings Call
You can ask Aime
What guidance did Telix's management provide for the next earnings period?Did Telix beat or miss consensus estimates last quarter?What is the market's earnings forecast for Telix next quarter?What were the key takeaways from Telix’s earnings call?What were the key takeaways from Telix's earnings call?What does Telix do and what are its main business segments?What is Telix's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Telix year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
